Cargando…
Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas
Retinal hemangioblastomas are the most common manifestation of Von Hippel-Lindau (VHL) disease [1-3]. While peripheral retinal hemangioblastomas may be treated by thermal laser treatment or cryotherapy, optic nerve and macular lesions are more difficult to treat [4, 5]. Based on the theoretical bene...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032222/ https://www.ncbi.nlm.nih.gov/pubmed/21293730 http://dx.doi.org/10.2174/1874364101004010066 |
_version_ | 1782197431158439936 |
---|---|
author | Hrisomalos, Frank N Maturi, Raj K. Pata, Veena |
author_facet | Hrisomalos, Frank N Maturi, Raj K. Pata, Veena |
author_sort | Hrisomalos, Frank N |
collection | PubMed |
description | Retinal hemangioblastomas are the most common manifestation of Von Hippel-Lindau (VHL) disease [1-3]. While peripheral retinal hemangioblastomas may be treated by thermal laser treatment or cryotherapy, optic nerve and macular lesions are more difficult to treat [4, 5]. Based on the theoretical benefit of administering anti-VEGF treatment, intra-vitreally administered bevacizumab (Avastin, a general pan-VEGF inhibitor) is attractive [6, 7]. Several short-term case series using ranibizumab (Lucentis, mAb fragment of bevacizumab with stronger affinity for VEGF-A) have shown it has promising but minimal success on most VHL-related hemangioblastomas [8, 9]. A comprehensive study by Wong et al. examined 5 patients over a period up to 61 weeks (47 ± 14 weeks) while Michels et al. examined one patient over a period of 4 months. Due to the short-term nature of these studies, we attempted long-term bevacizumab treatment over 60 months in a monocular subject with progressive visual loss due to a VHL associated macular and optic nerve hemangioblastoma. Over the treatment regimen of 15 injections, visual acuity improved 25 letters, OCT thickness improved from 646 um to 424 um, and structural lesions stabilized while exudates and edema resolved. |
format | Text |
id | pubmed-3032222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-30322222011-02-03 Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas Hrisomalos, Frank N Maturi, Raj K. Pata, Veena Open Ophthalmol J Article Retinal hemangioblastomas are the most common manifestation of Von Hippel-Lindau (VHL) disease [1-3]. While peripheral retinal hemangioblastomas may be treated by thermal laser treatment or cryotherapy, optic nerve and macular lesions are more difficult to treat [4, 5]. Based on the theoretical benefit of administering anti-VEGF treatment, intra-vitreally administered bevacizumab (Avastin, a general pan-VEGF inhibitor) is attractive [6, 7]. Several short-term case series using ranibizumab (Lucentis, mAb fragment of bevacizumab with stronger affinity for VEGF-A) have shown it has promising but minimal success on most VHL-related hemangioblastomas [8, 9]. A comprehensive study by Wong et al. examined 5 patients over a period up to 61 weeks (47 ± 14 weeks) while Michels et al. examined one patient over a period of 4 months. Due to the short-term nature of these studies, we attempted long-term bevacizumab treatment over 60 months in a monocular subject with progressive visual loss due to a VHL associated macular and optic nerve hemangioblastoma. Over the treatment regimen of 15 injections, visual acuity improved 25 letters, OCT thickness improved from 646 um to 424 um, and structural lesions stabilized while exudates and edema resolved. Bentham Open 2010-10-21 /pmc/articles/PMC3032222/ /pubmed/21293730 http://dx.doi.org/10.2174/1874364101004010066 Text en © Hrisomalos et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Hrisomalos, Frank N Maturi, Raj K. Pata, Veena Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas |
title | Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas |
title_full | Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas |
title_fullStr | Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas |
title_full_unstemmed | Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas |
title_short | Long-Term Use of Intravitreal Bevacizumab (Avastin) for the Treatment of Von Hippel-Lindau Associated Retinal Hemangioblastomas |
title_sort | long-term use of intravitreal bevacizumab (avastin) for the treatment of von hippel-lindau associated retinal hemangioblastomas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032222/ https://www.ncbi.nlm.nih.gov/pubmed/21293730 http://dx.doi.org/10.2174/1874364101004010066 |
work_keys_str_mv | AT hrisomalosfrankn longtermuseofintravitrealbevacizumabavastinforthetreatmentofvonhippellindauassociatedretinalhemangioblastomas AT maturirajk longtermuseofintravitrealbevacizumabavastinforthetreatmentofvonhippellindauassociatedretinalhemangioblastomas AT pataveena longtermuseofintravitrealbevacizumabavastinforthetreatmentofvonhippellindauassociatedretinalhemangioblastomas |